Skip to main content

Table 1 Description of interventions assessed

From: Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis

Intervention Description Health facility stay Laboratory/imaging
Acute myocardial infarction   9 hospital bed days at tertiary level CBC, blood glucose, PT, INR, aPTT and serum lipid profile (3 times) plus ECG and RFT twice
 Aspirin Aspirin 325 mg po daily 30 days
 ACE-inhibitor Enalapril 20 mg po daily for 30 days
 Beta-blocker Atenolol 50 mg po daily for 28 days
 Aspirin + clopidogrel Aspirin 325 mg + clopidogrel 300 mg 30 days
 Thrombolytic Streptokinase 1.5 million i-u
 Primary PCI Insertion of ballon-tipped catheter with stent into blocked area 6 hospital bed days at tertiary level
Post-acute myocardial infarction
 Aspirin ASA 100 mg po daily 4 hospital visit per year (year 1–3)
3 hospital visit per year (year 4–10) at primary hospital
CBC, LFT, RFT, serum lipid profile, serum electrolyte
 ACE-inhibitor Enalapril 20 mg po daily
 Beta-blocker Atenolol 50 mg po daily
 Statin Simvastatin 40 mg po daily
Acute stroke
 Aspirin Aspirin 160 mg po daily for 1 month 30 hospital bed days at level 3 CBC,PT, INR, aPTT, serum glucose, serum lipid profile, RFT,LFT and serum electrolyte plus brain CT,ECG &CXR once
Post-acute stroke
 Aspirin Aspirin 100 mg po daily 4 hospital visit per year (year 1–3)
3 hospital visit per year (year 4–10) at primary hospital
CBC, RFT, LFT, serum lipid profile, serum electrolyte
 ACE-inhibitor Enalapril 20 mg po daily
 Statin Simvastatin 40 mg po daily
Primary prevention of IHD and stroke
 Anti-hypertensive treatment for SBP (>140 or >160 mmHg) HCT 25 mg + Atenolol 50 mg po daily 4 visit to a health center for the first year followed by 3 visits per year for the remaining 9 years. Additionally, 20 % will have 1.5 visit per year at primary hospital RFT, serum lipid, blood glucose, U/A
 Cholesterol lowering treatment for total cholesterol (>5.7 or >6.2 mmol/l) Simvastatin 40 mg po daily LFT, serum lipid, blood glucose, U/A
 Combination drug treatment for absolute CVD risk (>5, >15, >25, >35 %) ASA 100 mg + Hydrochlorothiazide 25 mg + Atenolol 50 mg + Simvastatin 20 mg RFT, LFT, serum lipid, blood glucose
  1. The intervention packages for ‘acute MI’, ‘post-acute MI’, and ‘post-acute stroke’ were formed as combinations of the drugs under the single interventions during the same health facility stay and the same laboratory investigation requirements as the respective single interventions. A complete list of all the interventions is provided in Table 4
  2. MI myocardial infarction; IHD ischemic heart disease; SBP systolic blood pressure; CBC complete blood count; PT prothrombin time; ECG electrocardiogram; RFT renal function test; LFT liver function test; U/A urinalysis